There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN) and Cassava Sciences (SAVA) with bullish sentiments.
Regeneron (REGN)
Canaccord Genuity analyst John Newman maintained a Buy rating on Regeneron on February 22 and set a price target of $700.00. The company’s shares closed last Tuesday at $468.03.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 30.6% and a 49.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Allogene Therapeutics, Atara Biotherapeutics, and Palatin Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $657.86 average price target, which is a 43.6% upside from current levels. In a report issued on February 8, Leerink Partners also maintained a Buy rating on the stock with a $640.00 price target.
See today’s analyst top recommended stocks >>
Cassava Sciences (SAVA)
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Cassava Sciences yesterday and set a price target of $97.00. The company’s shares closed last Tuesday at $52.37.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 40.4% and a 44.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Tenax Therapeutics, and vTv Therapeutics.
Cassava Sciences has an analyst consensus of Strong Buy, with a price target consensus of $67.00, which is a 32.7% upside from current levels. In a report issued on February 16, Maxim Group also assigned a Buy rating to the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAVA:
